American Liver Foundation

First National Study to Assess the Prevalence of NAFLD to be Conducted by Federal Government

Retrieved on: 
Thursday, April 25, 2024
Congress, Fatty liver disease, ALF, Language, NAFLD, Liver disease, Risk, Hispanic, AHRQ, Overweight, Diabetes, FAST, Partnership, Agency, Research, American Liver Foundation, Disease, Obesity, Labour, NASH, Patient, Liver failure, Society, Metabolic syndrome, American Society of Transplantation, Liver transplantation, Prevalence, Dietary supplement

NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.

Key Points: 
  • NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.
  • New national study to assess prevalence of NAFLD to be conducted, ALF grateful to Congress and advocates.
  • "We are so grateful to Senator Bill Cassidy (R-LA) for his leadership in championing this effort on Capitol Hill.
  • In an online liver health quiz to assess risk factors, 93% of respondents received a positive result for being at risk for NAFLD.

American Liver Foundation Mourns the Passing of Congressman Donald Payne, Jr.

Retrieved on: 
Wednesday, April 24, 2024
Obesity, Diabetes, Family, Patient, Liver, Kidney, Liver disease, News, American Liver Foundation

FAIRFIELD, N.J., April 24, 2024 /PRNewswire/ -- Today, American Liver Foundation mourns the passing of a leader on Capitol Hill, the Honorable Donald Payne, Jr, (D-NJ). A champion for patients affected by diabetes, obesity, kidney and liver disease among others, he was devoted to addressing the needs of underserved communities.

Key Points: 
  • FAIRFIELD, N.J., April 24, 2024 /PRNewswire/ -- Today, American Liver Foundation mourns the passing of a leader on Capitol Hill, the Honorable Donald Payne, Jr, (D-NJ).
  • A champion for patients affected by diabetes, obesity, kidney and liver disease among others, he was devoted to addressing the needs of underserved communities.
  • American Liver Foundation mourns passing of Congressman Donald Payne, Jr. a champion for patients and the underserved.
  • "We are so grateful to Congressman Payne for his efforts to support our legislative priorities on behalf of liver patients and are deeply saddened by the unexpected news of his passing."

Boston Marathon Runners Go Again to Fight Liver Disease

Retrieved on: 
Friday, April 12, 2024
Congenital hepatic fibrosis, ALF, Liver disease, Primary sclerosing cholangitis, Health, Partnership, American Liver Foundation, History, Disease, Boston Marathon, Boston Athletic Association, Memory, Kostecki, Liver cancer, Running

NEW YORK, April 12, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Boston Marathon Official Charity Program for the 2024 Boston Marathon®, which takes place on Monday, April 15, 2024.

Key Points: 
  • 128th Annual Boston Marathon is Monday, April 15th
    NEW YORK, April 12, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Boston Marathon Official Charity Program for the 2024 Boston Marathon®, which takes place on Monday, April 15, 2024.
  • American Liver Foundation (ALF) runners participate in the 2024 Boston Marathon® to raise awareness of liver disease!
  • Since 1988, the American Liver Foundation Marathon Team has made a dramatic impact on the American Liver Foundation's mission.
  • The American Liver Foundation team is made up of novice to experienced runners, most of whom have a connection to liver disease.

Liver Patients, Families, and Medical Professionals Walk to End Liver Disease

Retrieved on: 
Thursday, April 11, 2024
Biliary atresia, ALF, News, Patient, Liver, Twin, Liver disease, Life, American Liver Foundation, Dietary supplement

NEW YORK, April 11, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) has begun hosting its annual Liver Life Walk for 2024 at 20 in-person locations across the country. Liver Life Walk raises funds and awareness for liver disease and helps create life-long connections and networks of support between patients, families and all those affected by liver disease.

Key Points: 
  • Liver Life Walk raises funds and awareness for liver disease and helps create life-long connections and networks of support between patients, families and all those affected by liver disease.
  • American Liver Foundation has begun hosting the 2024 Liver Life Walk at 20 in-person locations across the country.
    "
  • Liver Life Walk has been a signature event of American Liver Foundation since 1999," said Lorraine Stiehl, Chief Executive Officer of ALF.
  • "Funds raised through the Liver Life Walk empowers ALF to continue providing valuable resources to liver patients and their families, fund critical liver disease research, and advance public health education and improved patient treatment and coverage."

World-renowned Chefs Gather to Raise Awareness and Funds for Liver Disease

Retrieved on: 
Wednesday, April 3, 2024
Local, Education, Wrigley Mansion, ALF, American Liver Foundation, Research, Iron Chef, Iron Chef America, Restaurant, Heart, Table, Liver disease

NEW YORK, April 3, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) has teamed up with world-renowned culinary expert Chef Christopher Gross and Celebrity Chef Mark Tarbell from Iron Chef for FLAVORS, a national culinary event to be held in Phoenix, Arizona on May 22, 2024.

Key Points: 
  • ALF and world-renowned culinary expert Chef Christopher Gross team up for FLAVORS, a national culinary event on May 22.
  • "ALF is delighted for the return of FLAVORS with our founder, Chef Christopher," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
  • "The generosity of these chefs and those philanthropists attending help us continue to provide life-saving resources, support, research and education for the nearly 100 million of Americans affected by liver disease."
  • Chef Christopher will be joined by seven other local chefs, including Mark Tarbell, winner of 2007 "Iron Chef America".

American Liver Foundation Celebrates Donate Life Month with New Patient Resources, Programs and Support

Retrieved on: 
Monday, April 1, 2024
American Liver Foundation, Journey, Celebration, Liver disease, Environment, Caregiver, Patient, Social media, News, Liver transplantation, MD, ALF, North Shore University Hospital, Liver, Partner, Fatigue, Sadness, Dentistry

April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.

Key Points: 
  • April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.
  • "An informed patient is critically important to making the best decisions about care and ensuring the most favorable outcomes," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation and caregiver to a transplant recipient.
  • Liver patients, families and loved ones are invited to celebrate the gift of life and the importance of liver transplantation.
  • Throughout Donate Life Month ALF encourages patients, caregivers and organ donors to be part of the national conversation!

American Liver Foundation Statement on FDA Approval of Resmetirom

Retrieved on: 
Thursday, March 14, 2024
HCC, Liver failure, American Liver Foundation, Fatty liver disease, Liver disease, Disease, Caregiver, Risk, Cirrhosis, Inflammation, Chairperson, Patient, Life, Liver transplantation, Hope, Doctor of Philosophy, MASH, MD, ALF, Pharmacotherapy, Fibrosis, NASH, Hepatology, Hepatocellular carcinoma, NAFLD, FDA, Liver, Food, Pharmaceutical industry

FAIRFIELD, N.J., March 14, 2024 /PRNewswire/ -- Today, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis. NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease* (NAFLD) and causes inflammation in the liver and liver damage.

Key Points: 
  • NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease * (NAFLD) and causes inflammation in the liver and liver damage.
  • "American Liver Foundation applauds the FDA approval of the groundbreaking new drug therapy treatment, resmetirom, for patients with NASH who have progressed to fibrosis," said Lorraine Stiehl , Chief Executive Officer, American Liver Foundation.
  • American Liver Foundation offers many free resources to patients and families affected by liver disease.
  • *Note: The nomenclature for NAFLD and NASH recently changed to metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) respectively.

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Retrieved on: 
Wednesday, February 28, 2024
Oncology, Professional Services, Health, Finance, General Health, Pharmaceutical, Biotechnology, CANF, Non-alcoholic fatty liver disease, Psoriasis, CMS, Liver disease, ALT, Fatty liver disease, Patent, Use, Inflammation, CKD, Human, Partner, Patient, IP, NASH, Phase, American Liver Foundation, Pharmaceutical industry

(NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.

Key Points: 
  • (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
  • This invention addresses the use of Namodenoson for the reduction of liver fat in patients with NASH a clinical indication that is being developed by Can-Fite.
  • The Company also has a distribution agreement in Canada for its anti-inflammatory drug, Piclidenoson, for the treatment of psoriasis.
  • “This additional patent in Canada for fatty liver disease adds to our growing IP estate for this high-value indication of the Namodenoson drug candidate.

American Liver Foundation Announces Recipients of 2023 Liver Research Awards

Retrieved on: 
Thursday, January 25, 2024
Cirrhosis, Research, Fibrosis, ALF, COVID, Genetics, Liver cancer, Fatty liver disease, Disease, Patient, Liver, Doctor of Philosophy, Biomarker, American Liver Foundation, Lipid metabolism, Liver disease, Dietary supplement

FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research. Three researchers will receive a Liver Scholar Award, and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.

Key Points: 
  • Research topics include fatty liver disease, rare and pediatric liver disease, liver cancer, cirrhosis and more
    FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research.
  • Three researchers will receive a Liver Scholar Award , and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.
  • ALF announces $850,000 in awards to fund early career scientists in basic and translational liver disease research.
  • The 2023 research awards, totaling $850,000 over a three-year period, include research topics such as lipid metabolism, biomarkers, genetics, microbiome immune response, and liver environment, and address important questions in the pathophysiology of fatty liver disease (now called steatotic liver disease), pediatric liver disease , rare liver disease , liver cancer , fibrosis / cirrhosis , and alcohol-associated liver disease .

Non-alcoholic steatohepatitis (NASH) real-world evidence innovation further extends Verantos' lead in artificial intelligence for cardiometabolic conditions

Retrieved on: 
Monday, November 13, 2023
RWE, Hepatology, PALO, NAFLD, Natural language processing, Organization, Prevalence, AASLD, DSM-IV codes, Patient, RWD, American Liver Foundation, Intelligence, Obesity, Non-alcoholic fatty liver disease, Chronic liver disease, NASH, Medical device

PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions. The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.

Key Points: 
  • PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos , the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions.
  • The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.
  • "Verantos' advances in artificial intelligence afford life sciences organizations unprecedented real-world insights into metabolic diseases," said Dan Riskin, M.D., CEO of Verantos.
  • The number of cases is growing with the increasing prevalence of obesity and type 2 diabetes.